ArticleInternational journal of ophthalmology2026
Efficacy and safety of cyclosporine 1% eye drops for the treatment of pediatric blepharokeratoconjunctivitis.
Article in International journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the efficacy and safety of cyclosporine 1% (CsA) eye drops in patients affected by pediatric blepharokeratoconjunctivitis (PBKC).
methodsThis was a retrospective, single arm study of pediatric patients with PBKC. All patients received topical CsA 1% eye drops, administered three times daily for 2mo and then tapered during the third month. In the first treatment week, chloramphenicol and betamethasone eye drops were also given three times daily. Patients were examined at baseline (T0), 4wk (T1), 3mo (T2), and 12mo (T3). At each visit, slit-lamp evaluation of the anterior segment and anterior segment photography were performed. Disease activity and damage were assessed using the modified Hamada bimodal scoring system. Mean PBKC scores across time points were compared using one-way ANOVA, followed by Tukey's HSD post-hoc test.
resultsThirty-six pediatric patients with PBKC were enrolled, six are excluded for incomplete follow-up, leaving 30 patients (11 males, 19 females; mean age 7.71±3.86y) for analysis. The baseline activity score was 1.60±0.62 and decreased significantly at all time points (T1: 0.53±0.51; T2: 0.34±0.76; T3: 0.47±0.86;
conclusionCsA 1% eye drops effectively control the signs and symptoms of PBKC in pediatric patients and demonstrate a favorable safety profile, supporting their used as a valid therapeutic option in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.